Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,537
  • Shares Outstanding, K 8,178
  • Annual Sales, $ 120,770 K
  • Annual Income, $ 32,690 K
  • EBIT $ 36 M
  • EBITDA $ 38 M
  • 60-Month Beta -0.44
  • Price/Sales 0.32
  • Price/Cash Flow 0.97
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 3.50
  • Growth Rate Est. (year over year) +28,442.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.59 +0.11%
on 03/27/26
7.30 -37.12%
on 03/09/26
-0.83 (-15.31%)
since 02/27/26
3-Month
3.92 +17.09%
on 02/23/26
19.15 -76.03%
on 01/05/26
-12.68 (-73.42%)
since 12/26/25
52-Week
3.92 +17.09%
on 02/23/26
19.15 -76.03%
on 01/05/26
-2.29 (-33.28%)
since 03/27/25

Most Recent Stories

More News
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 29, 2026 /PRNewswire/ --

ATRA : 4.59 (-2.55%)
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options

ATRA : 4.59 (-2.55%)
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:  ...

ATRA : 4.59 (-2.55%)
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Atara Biotherapeutics, Inc. (“Atara” or...

ATRA : 4.59 (-2.55%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain...

ATRA : 4.59 (-2.55%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA ) investors concerning the Company’s...

ATRA : 4.59 (-2.55%)
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA

The DJS Law Group reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA ) for violations of §§10(b) and...

ATRA : 4.59 (-2.55%)
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ...

ATRA : 4.59 (-2.55%)
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA ) on behalf of investors concerning the...

ATRA : 4.59 (-2.55%)
INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Atara Biotherapeutics, Inc. (“Atara” or the “Company”)...

ATRA : 4.59 (-2.55%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 5.26
2nd Resistance Point 5.13
1st Resistance Point 4.86
Last Price 4.59
1st Support Level 4.45
2nd Support Level 4.32
3rd Support Level 4.05

See More

52-Week High 19.15
Fibonacci 61.8% 13.33
Fibonacci 50% 11.53
Fibonacci 38.2% 9.74
Last Price 4.59
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.